Hiv-specific t cells: Strategies for fighting a moving target

Current HIV Research

Volumn 8, Issue 8, 2010, Pages 587-595

  Mckinnon, Lyle R ^a,b   Kaul, Rupert ^a,b   Herman, Melissa ^c   Plummer, Francis A ^b,c,d   Ball, T Blake ^b,c,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c UNIVERSITY OF MANITOBA   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Cell mediated immunity; Clade; HIV; Vaccine

Indexed keywords

EPITOPE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROTEOME; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLELE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLADISTICS; CROSS REACTION; CYTOKINE PRODUCTION; DRUG CROSS REACTIVITY; DRUG DEVELOPMENT; ESCAPE BEHAVIOR; GENETIC VARIABILITY; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; MUCOSA; NONHUMAN; PANDEMIC; VACCINATION; VIRUS LOAD; VIRUS STRAIN;

AIDS VACCINES; GENETIC VARIATION; HIV; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 78650953242     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210794088245     Document Type: Article

References (136)

1. Walker BD, Burton DR. Toward an AIDS vaccine. Science 2008; 320: 760-4.
2. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 2010; 464: 224-31.
3. Zinkernagel RM. The challenges of an HIV vaccine enterprise. Science 2004; 303: 1294-7; author reply 1294-7.
4. Amanna IJ, Messaoudi I and Slifka MK. Protective immunity following vaccination: how is it defined? Hum Vaccin 2008; 4: 316-9.
5. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009; 15: 866-70.
6. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100: 4144-9.
7. McMichael A, Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat Rev Immunol 2002; 2: 283-91.
8. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650-5.
9. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103-10.
10. Trachtenberg E, Korber B, Sollars C, et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med 2003; 9: 928-35.
11. Fowke KR, Kaul R, Rosenthal KL, et al. HIV-1-specific cellular immune responses among HIV-1-resistant sex workers. Immunol Cell Biol 2000; 78: 586-95.
12. Rowland-Jones SL, Dong T, Fowke KR, et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998; 102: 1758-65.
13. Kaul R, Plummer FA, Kimani J, et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000; 164: 1602-11.
14. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008; 14: 617-21.
15. Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med 2005; 11: S54-62.
16. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60: 471-84.
17. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med 2008; 358: 1590-602.
18. Worobey M, Gemmel M, Teuwen DE, et al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 2008; 455: 661-4.
19. Rambaut A, Posada D, Crandall KA, Holmes EC. The causes and consequences of HIV evolution. Nat Rev Genet 2004; 5: 52-61.
20. Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008; 197: 707-13.
21. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007; 195: 1177-80.
22. Vasan A, Renjifo B, Hertzmark E, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42: 843-52.
23. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3: 205-11.
24. Goulder PJ, Watkins DI. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 2004; 4: 630-40.
25. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3: 212-7.
26. Price DA, Goulder PJ, Klenerman P, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997; 94: 1890-5.
27. Draenert R, Le Gall S, Pfafferott KJ, et al. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med 2004; 199: 905-15.
28. Barouch DH, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415: 335-9.
29. Vezys V, Masopust D, Kemball CC, et al. Continuous recruitment of naive T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection. J Exp Med 2006; 203: 2263-9.
30. [Almeida JR, Price DA, Papagno L, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007; 204: 2473-85.
31. Allen TM, Yu XG, Kalife ET, et al. De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol 2005; 79: 12952-60.
32. Feeney ME, Tang Y, Pfafferott K, et al. HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol 2005; 174: 7524-30.
33. [Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009; 206: 1253-72.
34. Iversen AK, Stewart-Jones G, Learn GH, et al. Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat Immunol 2006; 7: 179-89.
35. Leslie A, Kavanagh D, Honeyborne I, et al. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med 2005; 201: 891-902.
36. Goulder PJ, Brander C, Tang Y, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001; 412: 334-8.
37. Leslie AJ, Pfafferott KJ, Chetty P, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10: 282-9.
38. Allen TM, Altfeld M, Geer SC, et al. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005; 79: 13239-49.
39. Wilson SE, Pedersen SL, Kunich JC, et al. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection. AIDS Res Hum Retroviruses 1998; 14: 925-37.
40. Keating SM, Bollinger RC, Quinn TC, Jackson JB and Carruth LM. Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays. AIDS Res Hum Retroviruses 2002; 18: 1067-79.
41. Durali D, Morvan J, Letourneur F, et al. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. J Virol 1998; 72: 3547-53.
42. Dorrell L, Willcox BE, Jones EY, et al. Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53. Eur J Immunol 2001; 31: 1747-56.
43. Cao H, Kanki P, Sankale JL, et al. Cytotoxic T-lymphocyte cross reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J Virol 1997; 71: 8615-23.
44. Yu XG, Lichterfeld M, Perkins B, et al. High degree of inter-clade cross-reactivity of HIV-1-specific T cell responses at the single peptide level. Aids 2005; 19: 1449-56.
45. Geels MJ, Dubey SA, Anderson K, et al. Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation. J Virol 2005; 79: 11247-58.
46. Coplan PM, Gupta SB, Dubey SA, et al. Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J Infect Dis 2005; 191: 1427-34.
47. Barugahare B, Baker C, K'Aluoch O, et al. Human immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition. J Virol 2005; 79: 4132-9.
48. McKinnon LR, Ball TB, Kimani J, et al. Cross-clade CD8(+) T-cell responses with a preference for the predominant circulating clade. J Acquir Immune Defic Syndr 2005; 40: 245-9.
49. Currier JR, Dowling WE, Wasunna KM, et al. Detection of high frequencies of HIV-1 cross-subtype reactive CD8 T lymphocytes in the peripheral blood of HIV-1-infected Kenyans. Aids 2003; 17: 2149-57.
50. Cao H, Mani I, Vincent R, et al. Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda. J Infect Dis 2000; 182: 1350-6.
51. Currier JR, Visawapoka U, Tovanabutra S, et al. CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: use of multiple peptide sets increases the detectable breadth of the CTL response. BMC Immunol 2006; 7: 8.
52. Geldmacher C, Currier JR, Gerhardt M, et al. In a mixed subtype epidemic, the HIV-1 Gag-specific T-cell response is biased towards the infecting subtype. Aids 2007; 21: 135-43.
53. Chen J, Hong K, Jia M, et al. Human immunodeficiency virus type 1 specific cytotoxic T lymphocyte responses in Chinese infected with HIV-1 B'/C Recombinant (CRF07_BC). Retrovirology 2007; 4: 62.
54. Yusim K, Kesmir C, Gaschen B, et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 2002; 76: 8757-68.
55. Brander C, Frahm N, Walker BD. The challenges of host and viral diversity in HIV vaccine design. Curr Opin Immunol 2006; 18: 430-7.
56. Altfeld M, Allen TM, Yu XG, et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 2002; 420: 434-9.
57. Clarke T. Bad news for HIV Vaccines? Nature 2002.
58. Bailey JR, O'Connell K, Yang HC, et al. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol 2008; 82: 7395-410.
59. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-93.
60. Buchbinder S. Putting Vaccines Back into the Prevention Puzzle. In: Microbicides. Pittsburgh, USA, 2010.
61. Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006; 194: 1650-60.
62. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296: 2354-60.
63. Santra S, Korber BT, Muldoon M, et al. A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci USA 2008; 105: 10489-94.
64. Santra S, Liao HX, Zhang R, et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med; 16: 324-8.
65. Barouch DH, O'Brien KL, Simmons NL, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med; 16: 319-23.
66. Rolland M, Nickle DC, Mullins JI. HIV-1 group M conserved elements vaccine. PLoS Pathog 2007; 3: e157.
67. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13: 46-53.
68. Altfeld M, Addo MM, Shankarappa R, et al. Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol 2003; 77: 7330-40.
69. Frahm N, Kaufmann DE, Yusim K, et al. Increased sequence diversity coverage improves detection of HIV-specific T cell responses. J Immunol 2007; 179: 6638-50.
70. Bansal A, Gough E, Ritter D, et al. Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients. Aids 2006; 20: 353-60.
71. Rutebemberwa A, Currier JR, Jagodzinski L, et al. HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides. Aids 2005; 19: 1165-72.
72. McKinnon LR, Mao X, Kimani J, et al. Epitope mapping of HIV specific CD8+ T cells in a cohort dominated by clade A1 infection. PLoS One 2009; 4: e6965.
73. Precopio ML, Betts MR, Parrino J, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 2007; 204: 1405-16.
74. Beveridge NE, Price DA, Casazza JP, et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007; 37: 3089-100.
75. Darrah PA, Patel DT, De Luca PM, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13: 843-50.
76. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-12.
77. Weninger W, Crowley MA, Manjunath N and von Andrian UH. Migratory properties of naive, effector, and memory CD8(+) T cells. J Exp Med 2001; 194: 953-66.
78. Seder RA, Darrah PA and Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8: 247-58.
79. Harty JT, Badovinac VP. Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol 2008; 8: 107-19.
80. Miller JD, van der Most RG, Akondy RS, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008; 28: 710-22.
81. Addo MM, Yu XG, Rathod A, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003; 77: 2081-92.
82. Betts MR, Ambrozak DR, Douek DC, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001; 75: 11983-91.
83. Cao J, McNevin J, Holte S, Fink L, Corey L, McElrath MJ. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 2003; 77: 6867-78.
84. Moore JP, Cao Y, Qing L, et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995; 69: 101-9.
85. Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med 2008; 14: 623-8.
86. Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3: 1061-8.
87. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci USA 2005; 102: 7239-44.
88. Day CL, Kiepiela P, Leslie AJ, et al. Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection. J Virol 2007; 81: 434-8.
89. van Grevenynghe J, Procopio FA, He Z, et al. Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med 2008; 14: 266-74.
90. Calarota SA, Foli A, Maserati R, et al. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol 2008; 180: 5907-15.
91. McKinnon LR, Ball TB, Wachihi C, et al. Epitope cross-reactivity frequently differs between central and effector memory HIV specific CD8+ T cells. J Immunol 2007; 178: 3750-6.
92. Yang OO, Sarkis PT, Trocha A, Kalams SA, Johnson RP, Walker BD. Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL. J Immunol 2003; 171: 3718-24.
93. Bennett MS, Ng HL, Ali A, Yang OO. Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect crossclade antiviral activity. J Infect Dis 2008; 197: 390-7.
94. Valentine LE, Piaskowski SM, Rakasz EG, Henry NL, Wilson NA, Watkins DI. Recognition of escape variants in ELISPOT does not always predict CD8+ T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences. J Virol 2008; 82: 575-81.
95. Kuerten S, Nowacki TM, Kleen TO, Asaad RJ, Lehmann PV, Tary-Lehmann M. Dissociated production of perforin, granzyme B, and IFN-gamma by HIV-specific CD8(+) cells in HIV infection. AIDS Res Hum Retroviruses 2008; 24: 62-71.
96. Snyder-Cappione JE, Divekar AA, Maupin GM, Jin X, Demeter LM, Mosmann TR. HIV-specific cytotoxic cell frequencies measured directly ex vivo by the Lysispot assay can be higher or lower than the frequencies of IFN-gamma-secreting cells: anti-HIV cytotoxicity is not generally impaired relative to other chronic virus responses. J Immunol 2006; 176: 2662-8.
97. Turk G, Gherardi MM, Laufer N, et al. Magnitude, Breadth and Functional Profile of T-Cell Responses During Hiv Primary Infection with B and Bf Viral Variants. J Virol 2008; 82: 2853-66.
98. Turner SJ, Doherty PC, McCluskey J and Rossjohn J. Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol 2006; 6: 883-94.
99. Klenerman P, Rowland-Jones S, McAdam S, et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 1994; 369: 403-7.
100. Mongkolsapaya J, Dejnirattisai W, Xu XN, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003; 9: 921-7.
101. Schnell FJ, Alberts-Grill N, Evavold BD. CD8+ T cell responses to a viral escape mutant epitope: active suppression via altered SHP-1 activity. J Immunol 2009; 182: 1829-35.
102. Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 1991; 252: 1308-10.
103. Plebanski M, Lee EA, Hannan CM, et al. Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. Nat Med 1999; 5: 565-71.
104. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167-75.
105. Kappos L, Comi G, Panitch H, et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000; 6: 1176-82.
106. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999; 50: 201-12.
107. Leslie A, Price DA, Mkhize P, et al. Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. J Immunol 2006; 177: 4699-708.
108. Geldmacher C, Metzler IS, Tovanabutra S, et al. Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response. Blood 2009; 114: 1553-62.
109. Price DA, West SM, Betts MR, et al. T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity 2004; 21: 793-803.
110. Dong T, Stewart-Jones G, Chen N, et al. HIV-specific cytotoxic T cells from long-term survivors select a unique T cell receptor. J Exp Med 2004; 200: 1547-57.
111. Turnbull EL, Lopes AR, Jones NA, et al. HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently. J Immunol 2006; 176: 6130-46.
112. Price DA, Asher TE, Wilson NA, et al. Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. J Exp Med 2009; 206: 923-36.
113. Kosmrlj A, Read EL, Qi Y, et al. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 2010; 465: 350-4.
114. Bailey JR, Williams TM, Siliciano RF, Blankson JN. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med 2006; 203: 1357-69.
115. Brockman MA, Schneidewind A, Lahaie M, et al. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol 2007; 81: 12608-18.
116. Martinez-Picado J, Prado JG, Fry EE, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006; 80: 3617-23.
117. Navis M, Schellens I, van Baarle D, et al. Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol 2007; 179: 3133-43.
118. Chopera DR, Woodman Z, Mlisana K, et al. Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. PLoS Pathog 2008; 4: e1000033.
119. Migueles SA, Laborico AC, Imamichi H, et al. The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences. J Virol 2003; 77: 6889-98.
120. McKinnon LR, Capina R, Peters H, et al. Clade-specific evolution mediated by HLA-B*57/5801 in human immunodeficiency virus type 1 clade A1 p24. J Virol 2009; 83: 12636-42.
121. Yu XG, Lichterfeld M, Chetty S, et al. Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes. J Virol 2007; 81: 1619-31.
122. Hempel U BS, Pitakpolrat P, Phillips LC, et al. HLA-B*57 and B*58 Fail to Control HIV Clade AE in Thailand. In: Keystone HIV Vaccines. Banff, Canada, 2010.
123. Crawford H, Lumm W, Leslie A, et al. Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. J Exp Med 2009; 206: 909-21.
124. Frahm N, Kiepiela P, Adams S, et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006; 7: 173-8.
125. Goepfert PA, Lumm W, Farmer P, et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med 2008; 205: 1009-17.
126. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105: 7552-7.
127. Stone M, Keele BF, Ma ZM, et al. A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 2010; 84: 7083-95.
128. Haaland RE, Hawkins PA, Salazar-Gonzalez J, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009; 5: e1000274.
129. Bar KJ, Li H, Chamberland A, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010; 84: 6241-7.
130. Li H, Bar KJ, Wang S, et al. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog 2010; 6: e1000890.
131. Haase AT. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005; 5: 783-92.
132. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004; 303: 2019-22.
133. Norris PJ, Moffett HF, Brander C, et al. Fine specificity and crossclade reactivity of HIV type 1 Gag-specific CD4+ T cells. AIDS Res Hum Retroviruses 2004; 20: 315-25.
134. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-20.
135. Thongcharoen P, Suriyanon V, Paris RM, et al. A phase 1/2 comparative vaccine trial of the safety: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007; 46(1): 48-55.
136. Hansen SG, Vieville C, Whizin N, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15: 293-9.